Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PIK3C2A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PIK3C2A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PIK3C2A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PIK3C2A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PIK3C2A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PIK3C2A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PIK3C2A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PIK3C2A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00105958 | Skin | AK | positive regulation of endothelial cell migration | 25/1910 | 133/18723 | 1.89e-03 | 1.29e-02 | 25 |
GO:00480088 | Skin | AK | platelet-derived growth factor receptor signaling pathway | 13/1910 | 56/18723 | 3.55e-03 | 2.15e-02 | 13 |
GO:00030129 | Skin | AK | muscle system process | 64/1910 | 452/18723 | 4.32e-03 | 2.52e-02 | 64 |
GO:004826810 | Skin | AK | clathrin coat assembly | 6/1910 | 18/18723 | 7.04e-03 | 3.63e-02 | 6 |
GO:0010631110 | Skin | SCCIS | epithelial cell migration | 42/919 | 357/18723 | 1.45e-07 | 1.74e-05 | 42 |
GO:0090132110 | Skin | SCCIS | epithelium migration | 42/919 | 360/18723 | 1.82e-07 | 1.97e-05 | 42 |
GO:0090130110 | Skin | SCCIS | tissue migration | 42/919 | 365/18723 | 2.66e-07 | 2.62e-05 | 42 |
GO:0001667111 | Skin | SCCIS | ameboidal-type cell migration | 48/919 | 475/18723 | 1.78e-06 | 9.73e-05 | 48 |
GO:0009896112 | Skin | SCCIS | positive regulation of catabolic process | 49/919 | 492/18723 | 2.10e-06 | 1.09e-04 | 49 |
GO:0007173110 | Skin | SCCIS | epidermal growth factor receptor signaling pathway | 18/919 | 108/18723 | 4.95e-06 | 2.05e-04 | 18 |
GO:0038127110 | Skin | SCCIS | ERBB signaling pathway | 19/919 | 121/18723 | 6.72e-06 | 2.64e-04 | 19 |
GO:004354217 | Skin | SCCIS | endothelial cell migration | 32/919 | 279/18723 | 7.43e-06 | 2.80e-04 | 32 |
GO:0031331112 | Skin | SCCIS | positive regulation of cellular catabolic process | 41/919 | 427/18723 | 3.33e-05 | 8.88e-04 | 41 |
GO:0010632110 | Skin | SCCIS | regulation of epithelial cell migration | 31/919 | 292/18723 | 4.68e-05 | 1.16e-03 | 31 |
GO:0043434112 | Skin | SCCIS | response to peptide hormone | 38/919 | 414/18723 | 1.63e-04 | 3.28e-03 | 38 |
GO:0010634110 | Skin | SCCIS | positive regulation of epithelial cell migration | 20/919 | 176/18723 | 4.14e-04 | 6.68e-03 | 20 |
GO:00435345 | Skin | SCCIS | blood vessel endothelial cell migration | 20/919 | 176/18723 | 4.14e-04 | 6.68e-03 | 20 |
GO:001059415 | Skin | SCCIS | regulation of endothelial cell migration | 23/919 | 232/18723 | 1.10e-03 | 1.34e-02 | 23 |
GO:004800814 | Skin | SCCIS | platelet-derived growth factor receptor signaling pathway | 8/919 | 56/18723 | 5.73e-03 | 4.46e-02 | 8 |
GO:001059515 | Skin | SCCIS | positive regulation of endothelial cell migration | 14/919 | 133/18723 | 5.77e-03 | 4.48e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3C2A | SNV | Missense_Mutation | | c.185N>C | p.Arg62Thr | p.R62T | O00443 | protein_coding | tolerated_low_confidence(0.56) | benign(0.01) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PIK3C2A | SNV | Missense_Mutation | novel | c.4297N>T | p.His1433Tyr | p.H1433Y | O00443 | protein_coding | deleterious(0) | possibly_damaging(0.589) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PIK3C2A | SNV | Missense_Mutation | | c.742A>T | p.Ile248Leu | p.I248L | O00443 | protein_coding | tolerated_low_confidence(0.5) | benign(0.003) | TCGA-BH-A1FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PIK3C2A | SNV | Missense_Mutation | | c.4022G>A | p.Gly1341Glu | p.G1341E | O00443 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PIK3C2A | SNV | Missense_Mutation | rs374593257 | c.642N>G | p.Ile214Met | p.I214M | O00443 | protein_coding | tolerated_low_confidence(0.31) | benign(0.021) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
PIK3C2A | insertion | Frame_Shift_Ins | novel | c.256_257insA | p.Arg86LysfsTer6 | p.R86Kfs*6 | O00443 | protein_coding | | | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PIK3C2A | deletion | Frame_Shift_Del | | c.4970delN | p.Phe1657SerfsTer5 | p.F1657Sfs*5 | O00443 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PIK3C2A | insertion | In_Frame_Ins | novel | c.1373_1374insCACAGGAATACATAGTTGCCTATGGCAAAG | p.Val458_His459insThrGlyIleHisSerCysLeuTrpGlnArg | p.V458_H459insTGIHSCLWQR | O00443 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
PIK3C2A | deletion | Frame_Shift_Del | novel | c.2064delN | p.Phe688LeufsTer22 | p.F688Lfs*22 | O00443 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PIK3C2A | deletion | Frame_Shift_Del | novel | c.1423delT | p.Cys475ValfsTer34 | p.C475Vfs*34 | O00443 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | XL147 | PILARALISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BAY80-6946 | COPANLISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BYL719 | ALPELISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PI-103 | PI-103 | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PF-4691502 | PF-04691502 | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BKM120 | BUPARLISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | GSK2636771 | GSK-2636771 | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PX-866 | SONOLISIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | BGJ398 | INFIGRATINIB | |
5286 | PIK3C2A | ENZYME, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, TRANSPORTER | inhibitor | PKI-587 | GEDATOLISIB | |